1. Home
  2. UPBD vs KROS Comparison

UPBD vs KROS Comparison

Compare UPBD & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPBD
  • KROS
  • Stock Information
  • Founded
  • UPBD 1986
  • KROS 2015
  • Country
  • UPBD United States
  • KROS United States
  • Employees
  • UPBD N/A
  • KROS N/A
  • Industry
  • UPBD Diversified Commercial Services
  • KROS Biotechnology: Pharmaceutical Preparations
  • Sector
  • UPBD Consumer Discretionary
  • KROS Health Care
  • Exchange
  • UPBD Nasdaq
  • KROS Nasdaq
  • Market Cap
  • UPBD 1.7B
  • KROS 1.8B
  • IPO Year
  • UPBD 1995
  • KROS 2020
  • Fundamental
  • Price
  • UPBD $32.99
  • KROS $53.84
  • Analyst Decision
  • UPBD Buy
  • KROS Strong Buy
  • Analyst Count
  • UPBD 6
  • KROS 8
  • Target Price
  • UPBD $39.17
  • KROS $91.43
  • AVG Volume (30 Days)
  • UPBD 427.5K
  • KROS 407.2K
  • Earning Date
  • UPBD 10-31-2024
  • KROS 11-06-2024
  • Dividend Yield
  • UPBD 4.47%
  • KROS N/A
  • EPS Growth
  • UPBD 833.06
  • KROS N/A
  • EPS
  • UPBD 1.49
  • KROS N/A
  • Revenue
  • UPBD $4,259,426,999.00
  • KROS $651,000.00
  • Revenue This Year
  • UPBD $9.86
  • KROS $1,232.45
  • Revenue Next Year
  • UPBD $4.13
  • KROS $126.39
  • P/E Ratio
  • UPBD $21.53
  • KROS N/A
  • Revenue Growth
  • UPBD 7.43
  • KROS 8037.50
  • 52 Week Low
  • UPBD $26.50
  • KROS $27.31
  • 52 Week High
  • UPBD $38.72
  • KROS $73.00
  • Technical
  • Relative Strength Index (RSI)
  • UPBD 60.08
  • KROS 35.08
  • Support Level
  • UPBD $31.63
  • KROS $52.64
  • Resistance Level
  • UPBD $32.76
  • KROS $70.26
  • Average True Range (ATR)
  • UPBD 1.06
  • KROS 3.40
  • MACD
  • UPBD 0.09
  • KROS -1.42
  • Stochastic Oscillator
  • UPBD 69.94
  • KROS 6.84

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: